# Nuo Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Nuo Therapeutics, Inc.). ## Overview Nuo Therapeutics, Inc. is a U.S.-based commercial-stage medical device company focused on chronic wound care. Its core product is Aurix, an autologous cell-based therapy platform used in wound healing settings, supported by related centrifuge devices, packaging, and distribution arrangements. ## Products & services • Aurix branded chronic wound care product • Private label Aurix product for Smith+Nephew • Aurix centrifuge devices and related consumables • Product packaging, shipping, and fulfillment services • Distribution and sales agency arrangements - **Aurix branded product** (70%) — The company's own branded autologous wound care product sold through its sales network. - **Private label product** (15%) — Aurix supplied under Smith+Nephew's private label for U.S. distribution. - **License and distribution fees** (7%) — Upfront and ongoing fees tied to the Smith+Nephew distribution agreement. - **Centrifuge devices and related supplies** (8%) — Devices and supporting items used to prepare or deliver the Aurix therapy. - Aurix branded chronic wound care product - Private label Aurix product for Smith+Nephew - Aurix centrifuge devices and related consumables - Product packaging, shipping, and fulfillment services - Distribution and sales agency arrangements ## Customers Nuo sells primarily to wound care providers, especially hospital outpatient wound care clinics and related clinical settings. Its customers also include third-party sales representatives, distributors, and a large strategic partner, Smith+Nephew, which purchases private label product and acts as an interim sales agent for certain Aurix-branded sales. - **Hospital outpatient wound care clinics** (primary) — Buy Aurix for chronic wound treatment and clinical use after internal evaluation and reimbursement alignment. - **Wound care providers** (primary) — Clinics and providers that purchase the product to treat complex chronic wounds in outpatient settings. - **Smith+Nephew** (secondary) — Purchases private label Aurix product and supports distribution of Aurix-branded product to its customers. - **Sales agents and distributors** (secondary) — Third-party representatives that help generate orders and expand commercial coverage across U.S. markets. - **Hospital value analysis committees** (secondary) — Evaluate the product for clinical adoption and purchasing approval within hospital systems. - Hospital outpatient wound care clinics buying Aurix for chronic wounds - Wound care providers seeking therapies aligned with Medicare reimbursement - Smith+Nephew as private label distributor and interim sales agent - Independent sales agents and distributors expanding market access - Hospital value analysis committees evaluating clinical adoption ## Geography Nuo is centered on the United States, where it commercializes Aurix and builds its sales network. Its commercial footprint is concentrated in U.S. wound care markets, including multiple large western markets through a multi-state agreement with Pacific Medical, Inc. The company does not disclose meaningful non-U.S. revenue in the provided excerpts. - United States is the core commercial market - Western U.S. coverage expanded through Pacific Medical agreement - Sales are concentrated in hospital outpatient wound care clinics - Smith+Nephew private label distribution is U.S.-based - No disclosed country-level revenue outside the United States ## Strategy Nuo's strategy is to expand adoption of Aurix in chronic wound care by building relationships with wound care providers and hospital systems. It is also using a strategic distribution relationship with Smith+Nephew to broaden market access while continuing to sell its own branded product. - **Expand U.S. commercial coverage** (short-term) — Broader field coverage should increase awareness and access to Aurix among wound care providers. - **Drive hospital adoption and reimbursement support** (short-term) — Clinical approval and reimbursement execution are necessary for routine use in outpatient wound care. - **Leverage Smith+Nephew distribution** (medium-term) — The partnership can extend reach and add a second commercialization channel for Aurix. - Expand commercial adoption of Aurix in chronic wound care - Build a larger U.S. sales-agent and distributor network - Secure hospital value analysis committee approvals - Support reimbursement administration with Medicare contractors - Use Smith+Nephew to extend distribution and market reach ## Risks Nuo depends on successful reimbursement, clinical adoption, and execution by a relatively small commercial organization, which makes revenue growth sensitive to payer and provider acceptance. The company also faces product, distribution, and supply-chain risks tied to manufacturing, transfer pricing, and partner execution, especially under the Smith+Nephew arrangement. - **Reimbursement and coverage dependence** [high] — Aurix adoption relies on Medicare contractor administration and payer acceptance in wound care. - **Commercial adoption risk** [high] — Hospitals and clinics must approve the product through value analysis and clinical review before broad use. - **Partner concentration risk** [medium] — Smith+Nephew is an important distribution partner and private label customer. - **Manufacturing and supply-chain risk** [medium] — The company must manufacture, package, and ship product on time and at agreed transfer prices. - Reimbursement risk if Medicare administration is inconsistent - Slow hospital adoption due to committee review and clinical validation - Dependence on a growing but still limited sales network - Partner execution risk with Smith+Nephew distribution - Supply and transfer-pricing risk on private label device shipments ## Accounting Revenue recognition is important because the Smith+Nephew agreement includes an upfront distribution fee recognized ratably over five years, while product sales and commissions are recognized as transactions occur. Investors should also watch inventory, deferred revenue, and device purchase accounting because the company carries costs tied to centrifuge devices, packaging, shipping, and partner-related fulfillment. - **Deferred revenue from Smith+Nephew upfront fee** — Smooths revenue recognition versus cash receipt - **Product revenue recognition** — Impacts reported sales growth and gross profit - **Inventory and device cost accounting** — Affects cost of goods sold and margin profile - **Commission and fulfillment expense accruals** — Affects operating expense timing and comparability - Upfront distribution fee recognized over the contract term - Product revenue timing depends on shipments and sales activity - Deferred revenue reflects the Smith+Nephew upfront fee - Inventory and device purchases affect cost of sales and margins - Commission and fulfillment costs vary with partner sales --- *Last updated: 2026-04-29T04:42:07.468986+00:00*